Abstract 1753P
Background
Myxofibrosarcoma (MFS) are malignant tumors usually diagnosed in the extremities or trunk of elderly patients. Prognosis in this sarcoma subtype is dismal due to high risk of local recurrence. Our aim was to analyze the treatment results of patients (pts) diagnosed with localized myxofibrosarcoma, taking into account also surgical complications.
Methods
245 pts (51% male) with locally advanced myxofibrosarcoma treated in 2015-2020 were included in this retrospective analysis. Data on tumor characteristic and long-term survival and surgical complications were collected. Kaplan-Meier estimator with log-rank test was used for survival analysis. Median follow-up was 70 months (95%CI 67.2-79.7).
Results
The mean age was 63 years. 65% of the pts had no prior treatment, and 24% were referred after non-radical excision outside our center. Median size of the tumor was 9 cm (SD:6), 73% were high grade, 63% of cases were located on the lower limb (most often on the thigh). 82% had perioperative radiotherapy (72% preoperative). 22% of pts had preoperative chemotherapy. 76% pts underwent R0 resection, the others - R1. 56 pts (22%) had local recurrence and 29 of them had had another radical surgery, most of them extremity amputation (20 pts). 32% pts (79) developed metastases. Median OS was 115 months (95%CI 90.3-NA), while disease free-survival and local recurrence free survival (were 53.5 CI: (39.7 - NA) and not reached, respectively. In a multivariate analysis neoadjuvant radiotherapy was associated with longer LRFS (HR 0.36, 95%CI 0.21-0.65). T3 or T4 tumors and grade 2 or 3 tumors were associated with shorter DFS. Preoperative chemotherapy did not improve DFS (HR 0.82, 95%CI 0.51-1.33). 103 (42%) patient had complications after surgery resulting in prolonged wound healing, 40 of them had more than one complications, 10% patient required hospitalization due to complications, and 8.5% had another surgery for treatment of the complications.
Conclusions
Myxofibrosarcoma is a rare sarcoma subtype, local recurrences after adequate surgery are relatively common and most patient require adjuvant treatment and close follow-up. Treatment should be conducted in experienced sarcoma center with access to multidisciplinary team.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1372P - Advanced non-small cell lung carcinoma in the era of immunotherapy: Survival and the risk of multiple primary malignancies
Presenter: Nahla Ali
Session: Poster session 06
1373P - Measuring PFS in clinical trials and observational studies of patients with NSCLC: A scoping review
Presenter: Marjon Verschueren
Session: Poster session 06
1374P - Analysis of evolution of patient reported side effects during treatment for advanced NSCLC
Presenter: Helena Linardou
Session: Poster session 06
1375P - Sequential ctDNA profiling in patients with advanced non-small cell lung cancer: An interim analysis of the COPE randomized study
Presenter: Antoine Italiano
Session: Poster session 06
Resources:
Abstract
1376P - Early detection of disease progression in NSCLC patients undergoing immunotherapy through ctDNA analysis
Presenter: Virginia Calvo de Juan
Session: Poster session 06
1377P - Association of anatomic proximity of brain parenchymal metastasis to the CSF space and upfront stereotactic radiosurgery to subsequent leptomeningeal metastasis development in brain metastatic NSCLC
Presenter: Shoaib Bashir
Session: Poster session 06
Resources:
Abstract
1378P - Improvements in stage IV non-small cell lung cancer survival differ by race in the US
Presenter: Oluwaseun Ayoade
Session: Poster session 06
1379P - c-Met protein overexpression and telisotuzumab vedotin efficacy by biopsy age, type, and region in the LUMINOSITY phase II study
Presenter: Jair Bar
Session: Poster session 06
1380P - PK/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: The PIONeeR trial
Presenter: Joseph Ciccolini
Session: Poster session 06
1381P - Comparison between standard dose 75mg/m<sup>2</sup> and fixed dose at 50mg of cisplatin in the treatment of non-small cell lung cancer patients in term of response rate and toxicity profile
Presenter: Maher Salamoon
Session: Poster session 06